Valeant Comments On Issued Philidor Criminal Charges

LAVAL, Quebec, Nov. 17, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today learned that a criminal complaint was filed in relation to Philidor.  Gary Tanner and Andrew Davenport were charged in the matter. The company, former CEO, former CFO, and current executives have not been charged at this time. Gary Tanner ceased to be a Valeant employee on September 13, 2015, and Andrew Davenport has never been an employee of the Company.  The counts issued today include allegations that the charged parties engaged in actions to defraud Valeant as a company.  Valeant continues to cooperate with all relevant authorities in this matter.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:

Elif McDonald
[email protected]
514-856-3855
877-281-6642 (toll free)

Media:
Renée Soto
or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

SOURCE Valeant Pharmaceuticals International, Inc.

Related Links

http://www.valeant.com